Amygdala Neurosciences
509 Hale Street
Palo Alto
California
United States
Tel: 650-714-0553
Website: http://www.amygns.com/
Email: mailroom@amygns.com
About Amygdala Neurosciences
Amygdala Neurosciences is a biopharmaceutical company focused on the development and commercialization of first-in-class drug candidates for the treatment of addiction disorders. Amygdala was founded and is led by industry leaders and therapeutic experts who include: Executive Chairman Lou Lange, MD, PhD; Chief Science Officer Ivan Diamond, MD, PhD; President and Chief Executive Officer Peter Strumph; and Chief Financial Officer Adrienne MacMillan.YEAR FOUNDED:
2015
LEADERSHIP:
Executive Chairman and Founder: Lou Lange, MD, PhD
President, CEO and Founder: Peter Strumph
Founder and CSO: Ivan Diamond, MD, PhD
Founder and CFO: Adrienne MacMillan
TECHNOLOGY:
Please click here for Amygdala Neurosciences' technology.
9 articles about Amygdala Neurosciences
-
Amygdala Neurosciences Awarded $2.0 million NIH Grant to Conduct IND Enabling Studies
8/1/2023
Amygdala Neurosciences has been awarded a $2.0 million NIH grant to support the project titled "Investigational New Drug -enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder."
-
Amygdala Neurosciences Announces $5.6M Financing and Dr. Mack Mitchell's Expanded Role as CMO
11/18/2019
Funds will support current and planned Phase 2 clinical studies to assess ANS-6637 as a treatment for opioid, alcohol, and smoking/nicotine use disorders
-
Amygdala Neurosciences Awarded $1.35 million NIH Grant to Conduct Long Term, Phase 3 Enabling, Toxicology Studies
10/21/2019
ANS-6637, which is in Phase 2 clinical development, is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders.
-
Amygdala Neurosciences Announces Dosing of the First Patient in the NIH Funded Phase 2 Proof-Of-Concept study of ANS-6637 for the Treatment of Alcohol Use Disorder
10/17/2019
ANS-6637 is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders including alcohol use disorder.
-
Amygdala Neurosciences Announces Dosing the First Patients in the $12.4 Million NIH HEAL Initiative Funded SEARCH Program of Clinical Studies with ANS-6637
3/28/2019
Amygdala Neurosciences (a private company) announced today the start of dosing in a NIH/NIAID Phase 1b study to test the safety of ANS-6637, and how it effects the processing of drugs such buprenorphine that are processed by the same liver enzyme pathway.
-
Amygdala Neurosciences Announces the $12.4 Million HEAL Initiative Sponsored SEARCH (Safety and Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People with Opioid Use Disorder) Program of Phase 2 Clinical Studies
9/19/2018
Amygdala Neurosciences (a private company) announced today the SEARCH program of Phase 2 clinical studies which are sponsored by the National Institute of Allergy and Infectious Diseases (NIAID, a division of NIH) and are being conducted by the NIH Clinical Center and the Institute of Human Virology (IHV) at the University of Maryland School of Medicine.
-
Amygdala Neurosciences and NIAAA will Conduct a Phase 2 Clinical study of ANS-6637 for the Treatment of Alcohol Use Disorder
9/12/2018
Amygdala Neurosciences (a private company) announced today that the National Institute on Alcohol Abuse and Alcoholism (NIAAA, a division of NIH) will fund and conduct a Phase 2, human laboratory study of ANS-6637 for the treatment of alcohol use disorder.
-
Amygdala Initiates Phase Ib Clinical Study Of ANS-6637, The First-In-Class Selective ALDH2 Inhibitor In Development As A Treatment For Substance Use Disorder
8/1/2017
-
Amygdala Acquires GS-6637 From Gilead
2/16/2017